Gambro buy dents Baxter Q3 profit, but boosts sales
This article was originally published in Clinica
Executive Summary
Baxter International’s third-quarter profits were hit by $111m in costs related to its takeover of hemodialysis specialist Gambro, with earnings falling to $544m, versus $583m during the same period last year. But excluding these charges, income increased 4% to $655m, or $1.19 per diluted share, in line with previous guidance. On the plus side, the Gambro deal, agreed last year (www.clinica.co.uk, 4 December 2012), helped boost Baxter’s revenues, which grew 9% year-on-year to $3.77bn. The acquisition finally closed in September, months later than expected. Excluding Gambro’s contribution of $100m, Baxter’s Q3 sales were up 6%. For Q4, the company is predicting revenue growth of 12-13% (14-15% on a constant currency basis), which includes around $400m from Gambro, and earnings of $1.24-1.26 per diluted share. For full-year 2013, Baxter anticipates 6% revenue growth (7% at constant currency), including $500m Gambro sales, and earnings of $4.65-4.67 per diluted share.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.